Editas Medicine Inc logo

Editas Medicine Inc

4
NEW
NAS:EDIT (USA)  
$ 2.90 -0.12 (-3.97%) 07:08 PM EST
At Loss
P/B:
1.03
Market Cap:
$ 239.18M
Enterprise V:
$ 8.66M
Volume:
1.95M
Avg Vol (2M):
2.03M
Trade In:
Volume:
1.95M
At Loss
Avg Vol (2M):
2.03M

Business Description

Description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Name Current Vs Industry Vs History
Cash-To-Debt 7.21
Equity-to-Asset 0.6
Debt-to-Equity 0.17
Debt-to-EBITDA -0.19
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -4.8
Distress
Grey
Safe
Beneish M-Score -1.48
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 31
9-Day RSI 37.83
14-Day RSI 39.87
6-1 Month Momentum % -34.55
12-1 Month Momentum % -48.95

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.85
Quick Ratio 3.85
Cash Ratio 3.76
Days Sales Outstanding 16.75

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -9.3
Shareholder Yield % -0.44

Financials (Next Earnings Date:2024-11-01 Est.)

EDIT's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:EDIT

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Editas Medicine Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 67.033
EPS (TTM) ($) -2.36
Beta 1.91
Volatility % 100.05
14-Day RSI 39.87
14-Day ATR ($) 0.218966
20-Day SMA ($) 3.248
12-1 Month Momentum % -48.95
52-Week Range ($) 2.9 - 11.69
Shares Outstanding (Mil) 82.48

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Editas Medicine Inc Filings

Filing Date Document Date Form
No Filing Data

Editas Medicine Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Editas Medicine Inc Frequently Asked Questions

What is Editas Medicine Inc(EDIT)'s stock price today?
The current price of EDIT is $2.90. The 52 week high of EDIT is $11.69 and 52 week low is $2.90.
When is next earnings date of Editas Medicine Inc(EDIT)?
The next earnings date of Editas Medicine Inc(EDIT) is 2024-11-01 Est..
Does Editas Medicine Inc(EDIT) pay dividends? If so, how much?
Editas Medicine Inc(EDIT) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1